AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:APHB
CUSIPN/A
Phone+1-804-8272524
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,050.00%
Return on Equity-31.85%
Return on Assets-21.63%
Miscellaneous
EmployeesN/A
Outstanding Shares16,460,000
Market Cap$21.87
Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions
What is Ampliphi Biosciences' stock symbol?
Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."
How were Ampliphi Biosciences' earnings last quarter?
Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) announced its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.05. Ampliphi Biosciences had a negative return on equity of 31.85% and a negative net margin of 2,050.00%. View Ampliphi Biosciences' Earnings History.
When is Ampliphi Biosciences' next earnings date?
What price target have analysts set for APHB?
1 brokers have issued 1 year price targets for Ampliphi Biosciences' stock. Their predictions range from $6.00 to $6.00. On average, they expect Ampliphi Biosciences' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 435.7% from the stock's current price. View Analyst Ratings for Ampliphi Biosciences.
What is the consensus analysts' recommendation for Ampliphi Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampliphi Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Ampliphi Biosciences?
Ampliphi Biosciences saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 868,512 shares, an increase of 0.5% from the May 31st total of 864,065 shares. Based on an average trading volume of 155,247 shares, the days-to-cover ratio is currently 5.6 days. Currently, 5.6% of the shares of the company are short sold. View Ampliphi Biosciences' Current Options Chain.
Who are some of Ampliphi Biosciences' key competitors?
Some companies that are related to Ampliphi Biosciences include Ergomed (ERGO), Cardiome Pharma (COM), GB Sciences (GBLX), OncoCyte (OCX), InMed Pharmaceuticals (IMLFF), Navidea Biopharmaceuticals (NAVB), Botanix Pharmaceuticals (BOT), IntelGenx Technologies (IGX), BELLUS Health (BLU), Medicenna Therapeutics (MDNA), Destiny Pharma (DEST), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA) and OptiBiotix Health (OPTI).
Who are Ampliphi Biosciences' key executives?
Ampliphi Biosciences' management team includes the folowing people:
- Dr. Paul C. Grint, CEO & Director (Age 60)
- Mr. Steven R. Martin, Sr. VP & CFO (Age 57)
- Dr. Igor P. Bilinsky, Sr. VP & COO (Age 45)
- Mr. Michael Scott Salka, Consultant (Age 56)
- Dr. Alexander Gaidamaka, VP of Chemistry, Manufacturing & Control
Has Ampliphi Biosciences been receiving favorable news coverage?
News headlines about APHB stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ampliphi Biosciences earned a news sentiment score of 0.17 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.64 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Ampliphi Biosciences?
Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ampliphi Biosciences' stock price today?
One share of APHB stock can currently be purchased for approximately $1.12.
How big of a company is Ampliphi Biosciences?
Ampliphi Biosciences has a market capitalization of $21.87 million.
How can I contact Ampliphi Biosciences?
Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.
MarketBeat Community Rating for Ampliphi Biosciences (NYSEAMERICAN APHB)
MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote "Outperform" if you believe APHB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.
